In November 2025 the FDA began removing its strongest warnings — the black-box labels for cardiovascular disease, breast cancer, and dementia — from menopausal hormone therapy products. Labeling changes were approved in February 2026, and demand jumped.
By February 2026, about 5% of women aged 45–54 — one in twenty — had an estrogen-based HRT prescription, per Truveta's analysis of 130M+ patient records. Truveta measures the rise from a 2018 baseline: estrogen-patch prescriptions are up 184% since 2018, including a 25.7% jump in just July 2025–February 2026. (Reuters characterized the recent climb as a rough doubling since 2023.)
Multiple estradiol transdermal products from Amneal, Zydus, Sandoz, Noven and Viatris now have doses on the ASHP shortage list, which began tracking estrogen patches in January 2026 (more than a dozen brands and dosages by May). Amneal's Dotti, one of the most-prescribed patches, is among them. Anonymous industry sources told Reuters the squeeze could last up to three years — but that's a worst case; named menopause experts are more measured, with Mayo Clinic's Dr. Stephanie Faubion expecting supply to improve by the end of 2026.
Here's the gap: the FDA has not added estradiol patches to its own shortage database — Commissioner Marty Makary calls supply "tight but keeping up… something to manage" — even as ASHP, which logs shortages from front-line pharmacist and patient reports, lists more than a dozen patch products as short. That distance between what the regulator has formally declared and what women hit at the pharmacy counter is the structural reality of this market right now. See our full estrogen-patch shortage status and alternatives →
Several DTC telehealth platforms have stepped in, and many can prescribe non-patch estrogen — gel, cream, spray, oral or a vaginal ring — when your patch is unavailable. We've ranked the 10 platforms women are actually choosing between — by cost, formulary, and clinical depth — so you can pick one and move on.
Sources: FDA labeling-change records (Feb 2026); NBC News (May 10, 2026) and NBC News / Reuters (Apr 9, 2026); Truveta (Apr 9, 2026); ASHP Drug Shortages list (estradiol transdermal system); and AARP (Mar 13, 2026).